WT1 Expression in Circulating RNA as a Minimal Residual Disease Marker for AML Patients After Stem-Cell Transplantation

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Molecular Diagnosis & Therapy

• Publication date

  2015-07-03

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s40291-015-0147-2PMID 26138637
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Quantification of Cell-Free mSHOX2 Plasma DNA for Therapy Monitoring in Advanced Stage Non-Small Cell (NSCLC) and Small-Cell Lung Cancer (SCLC) Patients

  2015cited by this paper
• A multigene array for measurable residual disease detection in AML patients undergoing SCT

  2015cited by this paper
• Prospective Validation of a New Method of Monitoring Minimal Residual Disease in Childhood Acute Myelogenous Leukemia

  2014cited by this paper
• Peripheral Blood WT1 Expression Predicts Relapse in AML Patients Undergoing Allogeneic Stem Cell Transplantation

  2014cited by this paper
• Plasma Cell-Free DNA in Paediatric Lymphomas

  2013cited by this paper
• Circulating nucleic acids in plasma and serum (CNAPS): applications in oncology

  2013cited by this paper
• WT1 protein expression in astrocytic tumors and its relationship with cellular proliferation index

  2013cited by this paper
• Maintenance of complete remission after allogeneic stem cell transplantation in leukemia patients treated with Wilms tumor 1 peptide vaccine

  2013cited by this paper
• Wilms’ tumour suppressor gene 1 (WT1) is involved in the carcinogenesis of Lung cancer through interaction with PI3K/Akt pathway

  2013cited by this paper
• Hydrogen Sulfide Improves Drought Tolerance in Arabidopsis thaliana by MicroRNA Expressions

  2013cited by this paper
• Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia.

  2012cited by this paper
• LOH at 6q and 10q in fractionated circulating DNA of ovarian cancer patients is predictive for tumor cell spread and overall survival

  2012cited by this paper
• Quantification of BCR-ABL mRNA in Plasma/Serum of Patients with Chronic Myelogenous Leukemia

  2012cited by this paper
• Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials.

  2012cited by this paper
• Increased expression of tumor-associated antigens in pediatric and adult ependymomas: implication for vaccine therapy

  2012cited by this paper
• Estimation of molecular upper remission limit for monitoring minimal residual disease in peripheral blood of acute myeloid leukemia patients by WT1 expression.

  2012influential reference
• Oxygen-Dependent Gene Expression in Development and Cancer: Lessons Learned from the Wilms’ Tumor Gene, WT1

  2011cited by this paper
• Methods for isolation of cell-free plasma DNA strongly affect DNA yield.

  2011influential reference
• Risk factors for end stage renal disease in non-WT1-syndromic Wilms tumor.

  2011cited by this paper
• Isolation and cloning of microRNAs from recalcitrant plant tissues with small amounts of total RNA: a step-by step approach

  2011cited by this paper
• Phorbol-Ester Mediated Suppression of hASH1 Synthesis: Multiple Ways to Keep the Level Down

  2011cited by this paper
• Early reduction of WT1 transcripts during induction chemotherapy predicts for longer disease free and overall survival in acute myeloid leukemia

  2010cited by this paper
• Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study.

  2009cited by this paper
• Extracellular Tumor-Related mRNA in Plasma of Lymphoma Patients and Survival Implications

  2009cited by this paper
• Functional Unresponsiveness and Replicative Senescence of Myeloid Leukemia Antigen–specific CD8+ T Cells After Allogeneic Stem Cell Transplantation

  2009cited by this paper
• The new molecular biology of granulosa cell tumors of the ovary

  2009cited by this paper
• A Novel Nuclease Activity that is Activated by Ca2+ Chelated to EGTA

  2009cited by this paper
• Circulating nucleic acids (CNAs) and cancer--a survey.

  2007cited by this paper
• Ser‐249TP53 mutation in tumour and plasma DNA of hepatocellular carcinoma patients from a high incidence area in the Gambia, West Africa

  2004cited by this paper
• Monitoring Minimal Residual Disease in Leukemia Using Real-time Quantitative Polymerase Chain Reaction for Wilms Tumor Gene (WT1)

  2003cited by this paper
• p14ARF promoter hypermethylation in plasma DNA as an indicator of disease recurrence in bladder cancer patients.

  2002cited by this paper
• Real-time quantitative polymerase chain reaction

  2000cited by this paper
• Rearranged Ig heavy chain DNA is detectable in cell-free blood samples of patients with B-cell neoplasia.

  1997cited by this paper
• Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

  1987cited by this paper
• Preservation of algal and higher plant ribosomal RNA integrity during extraction and electrophoretic quantitation.

  1978cited by this paper
• Free DNA in the serum of cancer patients and the effect of therapy.

  1977cited by this paper

• Minimally invasive determination of pancreatic ductal adenocarcinoma (PDAC) subtype by means of circulating cell‐free RNA

  2024cites this paper
• Telomeric repeat-containing RNA is dysregulated in acute myeloid leukemia

  2023cites this paper
• Liquid biopsies and minimal residual disease in myeloid malignancies

  2023cites this paper
• Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy.

  2020cites this paper
• Bone Marrow WT1 Levels in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplasia: Clinically Relevant Time Points and 100 Copies Threshold Value.

  2018cites this paper
• Combined usage of Wilms' tumor gene quantitative analysis and multiparameter flow cytometry for minimal residual disease monitoring of acute myeloid leukemia patients after allogeneic hematopoietic stem cells transplantation

  2017cites this paper
• The Wilms Tumor-1 (WT1) rs16754 polymorphism is a prognostic factor in acute myeloid leukemia (AML): a meta-analysis

  2016cites this paper
• Should minimal residual disease guide therapy in AML?

  2015cites this paper
• Mediterranean Journal of Hematology and Infectious Diseases Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical Applications

  year unknowncites this paper